Francesca Colombo

I have been studying lung cancer genetics for over 12 years, since the start of my scientific career. I have been involved in the identification and functional characterization of genes and genetic variants associated with the development or progression of lung cancer, focusing on adenocarcinoma histotype. In particular, I have carried out genome-wide association studies (GWAS), using genotyping data obtained by SNP-array, I performed in vitro functional assays to test the effects of different allelic variants in coding or regulatory regions and I conducted analyses for the identification of quantitative expression trait loci (eQTLs), combining transcriptomic and genomic data. In recent years, I have extended my interests to pharmacogenetics/pharmacogenomics, particularly in the field of smoking cessation therapies and opioid therapy for cancer pain. In addition, I have also recently started working on pharmacogenomics of immune checkpoint inhibitors in patients with advanced lung cancer. I have extensive technical skills in cell-molecular biology and statistics competence. I also have experience in research management (e.g. planning experiments, coordinating collaborators). I currently collaborate with several clinicians, including medical oncologists, pneumologists and palliative care experts.

Colombo F

Cancer genetics Genetic epidemiology Population genetics Pharmacogenetics/Pharmacogenomics Transcriptomics Molecular oncology

Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants

SELP Asp603Asn and severe thrombosis in COVID-19 males

Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients

Read-through transcripts in lung: germline genetic regulation and correlation with the expression of other genes

Biomarkers for Early Cancer Diagnosis: Prospects for Success through the Lens of Tumor Genetics

Cigarette smoke alters the transcriptome of non-involved lung tissue in lung adenocarcinoma patients

Differential lung tissue gene expression in males and females: implications for the susceptibility to develop COPD

Corrigendum: Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure (Carcinogenesis (bgy145) DOI: 10.1093/carcin/bgy145)

Response to comments on 'Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure' by Farioli et al. and Oddone et al.

Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure

Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: A case report and literature review

Complex genetic control of lung tumorigenesis in resistant mice strains

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies

Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib

Genetic susceptibility variants for lung cancer: Replication study and assessment as expression quantitative trait loci

Human lung tissue transcriptome: Influence of sex and age

Expression quantitative trait analysis reveals fine germline transcript regulation in mouse lung tumors

Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma

Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series

Mouse Pulmonary Adenoma Susceptibility 1 Locus Is an Expression QTL Modulating Kras-4A

N6-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas